Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ga-68 DOTA-FAPI-4
- Development stage
- Unknown
- Lead developer
- SOFIE
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Ga-68 DOTA-FAPI-4 (also known as Ga-68 DOTA-FAPI-04) is a gallium-68-labeled small-molecule radiopharmaceutical diagnostic tracer that targets fibroblast activation protein (FAP). FAP is a type II transmembrane glycoprotein highly overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of more than 90% of epithelial carcinomas, as well as in active fibrotic and inflammatory diseases, while showing minimal expression in normal tissues. Developed originally by researchers at Heidelberg University and licensed to SOFIE Biosciences, Ga-68 DOTA-FAPI-4 is utilized in positron emission tomography (PET) imaging (often combined with CT or MRI) for the diagnosis, staging, and restaging of various solid tumors (such as gastric, pancreatic, head and neck, and colorectal cancers) and non-oncological conditions characterized by active tissue remodeling and fibrosis (such as liver fibrosis, lupus nephritis, and systemic sclerosis).
- Other names
- 68Ga-DOTA-FAPI-0468Ga-DOTA-FAPI-468Ga-FAPI-0468Ga-FAPI-4Ga-68 DOTA-FAPI-04Ga68 DOTA-FAPI-04Ga 68 DOTA-FAPI-04gallium Ga 68-DOTA-FAPI-04gallium Ga 68-DOTA-FAPI-4gallium Ga 68-FAPI-04gallium Ga 68-FAPI-4
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on Ga-68 DOTA-FAPI-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ga-68 DOTA-FAPI-4.